Impact of SARS-CoV-2 pandemic on viral suppression for young adults living with perinatally acquired HIV infection.
AIDS Care
; : 1-6, 2022 Aug 25.
Article
in English
| MEDLINE | ID: covidwho-2004875
ABSTRACT
We compared virological and immunological outcomes for young adults with perinatally-acquired HIV infection (YAPaHIV) in the year preceding, and year of, UK SARS-CoV-2 lockdown restrictions, in a service that maintained face-to-face appointments. Retrospective single-centre cohort analysis from; Period 1(P1) twelve months before the first national lockdown - 23rd March 2019-23rd March 2020, period 2(P2) twelve months of varied restrictions - 24th March 2020-24th March 2021. Data collected from electronic records included age, ethnicity, sex, HIV viral load (VL) (suppression ≤ 200 copies/ml), CD4 count (cells/µL), clinical events, and appointment frequency/modality. Descriptive analysis was comparative between periods. Of 177 YAPaHIV 56% were female, 86.9% were black, median age at lockdown 23 years (IQR 21-27). One individual was lost to follow up and excluded from subsequent analysis. 147/176 (83.5%) had a suppressed VL in P1 compared with 156/176 (88.6%) in P2. Of those detectable, median VL was 3200 copies/ml (IQR 925-36500) in P1, and 911copies/ml (IQR 317-52300) in P2. In P1, median CD4 was 675 (IQR 447-845.25). 32(18%) had a CD4 < 350 (median 216.5 [IQR 94.25-269.75]). 110 (59.5%) had a CD4 count in P2, median 551.5cells/µL (IQR 329.25-761.25). Thirty one had CD4 < 350 (median 202 [IQR 134.5-296]). Maintaining face-to-face appointments for vulnerable patients, with remote consultation for stable patients, maintained high levels of care engagement and suppression in a YAPaHIV cohort despite pandemic restrictions.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
AIDS Care
Journal subject:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Year:
2022
Document Type:
Article
Affiliation country:
09540121.2022.2114986
Similar
MEDLINE
...
LILACS
LIS